Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Common-Size Income Statement

Bristol-Myers Squibb Co., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net product sales 97.27 96.78 97.13 97.18 96.29
Alliance and other revenues 2.73 3.22 2.87 2.82 3.71
Revenues 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of products sold, excludes amortization of acquired intangible assets -23.76 -21.96 -21.43 -27.69 -30.90
Gross margin 76.24% 78.04% 78.57% 72.31% 69.10%
Marketing, selling and administrative -17.27 -16.93 -16.58 -18.02 -18.63
Research and development -20.66 -20.60 -21.98 -23.63 -23.52
Acquired IPRD -2.03 -1.77 -2.50 -29.48 0.00
Amortization of acquired intangible assets -20.10 -20.79 -21.61 -22.79 -4.34
Operating income (loss) 16.18% 17.96% 15.91% -21.60% 22.62%
Interest expense -2.59 -2.67 -2.88 -3.34 -2.51
Royalty and licensing income 3.31 2.78 2.30 2.08 5.20
Royalty income, divestitures 1.92 1.80 1.44 1.51 0.00
Equity investment income (losses), net -0.36 -1.74 1.61 2.89 1.05
Integration expenses -0.54 -0.95 -1.22 -1.69 -1.59
Loss on debt redemption 0.00 -0.58 -0.61 0.00 0.00
Divestiture gains 0.00 0.46 0.02 0.13 4.47
Litigation and other settlements 0.87 -0.39 -0.18 0.46 -0.29
Investment income 1.00 0.37 0.08 0.28 1.77
Provision for restructuring -0.81 -0.16 -0.36 -1.25 -1.15
Contingent consideration 0.02 0.02 1.17 4.13 -2.00
Acquisition expenses 0.00 0.00 0.00 0.00 -2.51
Other -0.24 -0.19 0.18 0.23 -6.03
Other income (expense), net 2.57% -1.25% 1.55% 5.44% -3.59%
Earnings (loss) before income taxes 18.75% 16.71% 17.46% -16.16% 19.03%
Provision for income taxes -0.89 -2.96 -2.34 -5.00 -5.79
Net earnings (loss) 17.86% 13.75% 15.12% -21.16% 13.23%
Noncontrolling interest -0.03 -0.04 -0.04 -0.05 -0.08
Net earnings (loss) attributable to BMS 17.83% 13.71% 15.08% -21.20% 13.15%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Earnings (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.